Risk of Developing Subsequent Primary Colorectal Cancers Among Non-Colorectal Cancer Survivors: Implications for Prevention and Screening.

Factors associated with participation in colorectal and breast cancer screening among cancer survivors: a systematic review and meta-analysis.

Subsequent malignant neoplasm among cancer survivors in the United States.

The Predictive Accuracy of PREDICT:A Personalized Decision-Making Tool for Southeast Asian Women With Breast Cancer

This population-based study suggests that several initial cancers are associated with elevated risk of CCA, and the increased risk may be due to shared genetic or environmental etiological factors between these malignancies.

Risk of Primary Lung Cancer in Women with Personal History of Breast Cancer and Subsequent Treatment Modality in an Integrated Health System.

BACKGROUND Breast cancer is the most common malignancy among U.S. women, and survivors face increased risk for subsequent malignancies, including lung cancer. Prior studies have reported associations between breast cancer treatments and lung cancer, but contemporary data remain limited. This study evaluates lung cancer risk following breast cancer, stratified by treatment modality, within an integrated health system. METHODS A retrospective cohort study of women diagnosed with breast cancer from 2010-2021 was conducted within Kaiser Permanente Northern California. Exclusion criteria included prior or early post-diagnosis lung cancer, early death, or lack of health plan membership. The primary outcome was subsequent primary lung cancer. Cumulative incidence was estimated using competing-risk methods, with death as a competing event. Associations with breast cancer treatments were evaluated using Fine-Gray regression. RESULTS Among 42,290 women followed for a median of 4.6 years, 324 (0.8%) developed lung cancer. The five-year cumulative incidence was 0.66%, with the highest incidence among current smokers (2.9%) and women aged 65-74 years and ≥75 years (1.1% and 1.2%, respectively). After adjusting for demographic, clinical, and tumor-related factors, breast cancer treatment exposures were not associated with lung cancer. Hispanic women demonstrated a significantly lower hazard of lung cancer compared with White women (HR 0.54, 95% CI 0.33-0.88). CONCLUSIONS Lung cancer risk among breast cancer survivors has increased over time, however risk was driven by patient-level factors, rather than breast cancer treatment exposures.

Cardiovascular disease in breast cancer patients receiving chemotherapy: epidemiology and risk factors

Evaluating the occurrence of new-onset CVD in women with breast cancer undergoing chemotherapy and identifying factors associated with increased risk of cardiovascular disease highlights the need for sustained cardiovascular surveillance in breast cancer survivors.

Integrating genetic predictors into subsequent breast cancer risk prediction in survivors of childhood cancer.

PURPOSE Female survivors of childhood cancer are at high risk for developing breast cancer. The contributions of most general population primary breast cancer genetic predictors to this risk have not been explored. METHODS Analyses included females who survived ≥5 years after their childhood cancer diagnosis with available array (N = 2096, subsequent breast cancer [SBC]=218) or whole-genome sequencing (WGS; N = 3292, SBC=101) data from the Childhood Cancer Survivor Study and St. Jude Lifetime Cohort. We computed 99 externally-validated primary breast cancer polygenic risk scores (PRS). Using deep-coverage WGS, ClinVar-annotated pathogenic/likely pathogenic (P/LP) variants in breast cancer susceptibility genes were identified. Cox proportional hazards models assessed associations with SBC risk, adjusting for treatments and genetic ancestry. RESULTS Among 5388 female survivors (genetic ancestry, European: N = 4,752; African: N = 444; East Asian: N = 192), 319 developed SBC. Most (90.9%) PRSs were nominally associated with SBC risk (P < 0.05), but effect sizes varied substantially. PRSs with superior discriminatory ability had greater genome-wide coverage (e.g., 6.4 million-variant PRS, HR per SD = 1.71, 95% CI = 1.43 to 2.05; P = 4.2x10-9) and 7.7-fold higher odds (P = 7.0x10-4) of including variants in multiple DNA damage repair pathways compared with PRSs with weaker risk associations. Among survivors with WGS, 1.6% carried P/LP variants in clinical testing panel genes, which was associated with a 7.4-fold greater risk (95% CI = 3.16 to 17.19). Including genetic factors improved SBC risk prediction by age 40 (P < 0.001) compared to treatment exposures alone. CONCLUSIONS Externally-validated primary breast cancer genetic susceptibility predictors are relevant for SBC risk prediction and should be prioritized for risk stratification in survivors.